Cost effective public longevity infrastructure solutions for healthy aging.
The most cost-effective public solutions for healthy ageing are cheap, old and under-delivered: vaccinating older adults through pharmacies, controlling blood pressure with pharmacist-led titration, physiotherapist-led balance and strength classes, hearing aids that are fitted and followed up, timely cataract surgery, medication reviews that stop drugs causing falls, and home safety changes for people already at risk. Social prescribing is promising. Publicly funded longevity clinics, biological-age tests, companion robots and fall-detection devices buy no healthy years at any price.
Cost-effectiveness for healthy ageing means healthy life-years per unit of public money in older adults, judged with the caveats the site's public-longevity section insists on — cost-effective is not cost-saving, and the discount rate and perspective change the number — and on that basis the ranking is dominated by cheap, old, under-delivered services. First: adult vaccination delivered through pharmacies with call-recall — influenza, pneumococcal, shingles — cost-effective in every evaluation and cost-saving in some, with the shingles vaccine's dementia signal a potential bonus. Second: hypertension control with pharmacist- or nurse-led protocol titration, generic drugs costing pennies against strokes costing tens of thousands, dominant in most models. Third: physiotherapist-led falls-prevention exercise, 23% fewer falls with high certainty, cost-effective against hip-fracture and care-home costs, and delivered to a small fraction of eligible adults. Fourth: hearing-aid provision that is fitted and followed up, 27% fewer falls over three years plus the cognition signal, cost-effective where uptake and adherence are supported. Fifth: timely cataract surgery, about a third fewer falls and a lower dementia hazard in cohorts, among the most cost-effective procedures in medicine. Sixth: structured deprescribing services, removing the sedatives and anticholinergics that cause falls and admissions, cost-effective on avoided harm. Seventh: targeted home hazard reduction, 38% fewer falls in people at elevated risk and no effect untargeted, so cost-effective only when targeted. Eighth: social prescribing and group activity, promising and less certain. Last, and not cost-effective at any price because they buy no healthy years: publicly funded longevity clinics, biological-age testing programmes, companion-robot and fall-detection device schemes.
- The most cost-effective healthy-ageing solutions are the cheapest and the least delivered.
- Vaccination and hypertension control are near-free to deliver and are among the highest-value services in medicine.
- Falls prevention, hearing aids and cataract surgery are trial-proven and capacity-limited.
- Deprescribing is cost-effective on avoided harm and sits unfunded in the medicines budget.
- Longevity clinics, biological-age testing and robot schemes are cost-ineffective at any price.
Healthy-ageing solutions ranked on cost per healthy year
Ranked on: cost per healthy life-year or QALY in older adults from trials and peer-reviewed economic evaluations, at conventional discount rates; strength of the outcome evidence; and the gap between cost-effectiveness and actual delivery.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Adult vaccination through pharmacies with call-recall | Cost-effective everywhere; cost-saving in some analyses | GRADE AEstablished |
| 2 | Hypertension control with pharmacist- or nurse-led titration | Dominant in most models | GRADE AEstablished |
| 3 | Physiotherapist-led falls-prevention exercise | High-certainty effect; cost-effective; scarcely delivered | GRADE AEstablished |
| 4 | Hearing-aid provision, fitted and followed up | 27% fewer falls over three years; cognition signal in high-risk group | GRADE AEstablished |
| 5 | Timely cataract surgery | Among the most cost-effective procedures in medicine | GRADE AEstablished |
| 6 | Structured deprescribing services | Cost-effective on avoided falls, delirium and admissions | GRADE BPromising |
| 7 | Targeted home hazard reduction | 38% fewer falls at elevated risk; nothing untargeted | GRADE BPromising |
| 8 | Social prescribing and group activity | Promising; evidence maturing | GRADE BPromising |
| 9 | Publicly funded longevity clinics, biological-age testing, robot and device schemes | Cost-ineffective at any price: no healthy years bought | GRADE DInsufficient or unsafe |
- 01
Adult vaccination through pharmacies with call-recall
GRADE AEstablishedCost-effective everywhere; cost-saving in some analysesInfluenza, pneumococcal, shingles and COVID vaccination of older adults, delivered by community pharmacies with registry-driven invitation. Cost-effective in essentially every evaluation, cost-saving in several, and the shingles vaccine's emerging dementia signal would improve the figure further. The remaining cost is uptake in deprived areas.
- 02
Hypertension control with pharmacist- or nurse-led titration
GRADE AEstablishedDominant in most modelsScreening, generic antihypertensives at pennies per day, and protocol titration by pharmacists or nurses, against strokes and heart attacks costing tens of thousands and ending independence. Control rates below half in most countries mean the value is largely unclaimed; pharmacist-led titration has randomised evidence for sustained reductions.
- 03
Physiotherapist-led falls-prevention exercise
GRADE AEstablishedHigh-certainty effect; cost-effective; scarcely deliveredBalance and functional exercise: 23% fewer falls across 108 randomised trials, 24% for balance-and-functional programmes, 34% with resistance training added. Cost-effective against hip-fracture treatment and care-home admission. Delivered to a small fraction of eligible older adults while fall deaths rise.
- 04
Hearing-aid provision, fitted and followed up
GRADE AEstablished27% fewer falls over three years; cognition signal in high-risk groupProperly fitted hearing aids with follow-up: falls reduced by 27% over three years; in the ACHIEVE trial the primary cognition result was null overall with a 61.6% slower decline confined to the highest-risk quartile. Cost-effective where uptake and adherence are supported; the device that is never worn is the wasted cost.
- 05
Timely cataract surgery
GRADE AEstablishedAmong the most cost-effective procedures in medicineExpedited first-eye surgery cut falls by 34% in a randomised trial and improved activity, confidence and mood; a well-controlled cohort found a hazard ratio of 0.71 for incident dementia. Cheap relative to its effect, and waiting lists are the cost driver.
- 06
Structured deprescribing services
GRADE BPromisingCost-effective on avoided falls, delirium and admissionsPharmacist-led review with authority to stop sedatives, anticholinergics and over-treatment in older adults on multiple medicines. Reduces harm in trials; the cost is a pharmacist's time and the return is avoided admissions. Funded patchily and invisible in most strategies.
- 07
Targeted home hazard reduction
GRADE BPromising38% fewer falls at elevated risk; nothing untargetedOccupational-therapist-led assessment and modification for people already at elevated fall risk: 38% fewer falls with high certainty. No effect in unselected populations, also with high certainty. Cost-effective only when targeted, which is the whole design.
- 08
Social prescribing and group activity
GRADE BPromisingPromising; evidence maturingLink workers, group exercise and activity programmes, befriending and day services. Loneliness predicts mortality; trials show wellbeing and function gains with cost-effectiveness evidence still accumulating. Worth funding, with evaluation built in.
- 09
Publicly funded longevity clinics, biological-age testing, robot and device schemes
GRADE DInsufficient or unsafeCost-ineffective at any price: no healthy years boughtLongevity clinic programmes, epigenetic-age testing, companion-robot rollouts and fall-detection device schemes have no evidence of adding healthy years at population scale, and several have trials showing nothing. Money spent on them is money not spent on rows one to eight.
What each solution costs, roughly, and what it buys
Order-of-magnitude costs and outcomes for healthy-ageing solutions
| Solution | Approximate cost per person | Outcome evidence | Delivery channel |
|---|---|---|---|
| Adult vaccination | Tens of dollars per dose | Cost-effective to cost-saving | Pharmacy; call-recall |
| Hypertension control | Pennies per day for drugs; pharmacist time | Dominant in models | Pharmacy; primary care |
| Falls-prevention exercise | Low hundreds per course | 23% fewer falls, high certainty | Physiotherapy; community classes |
| Hearing aids | Hundreds to low thousands, with fitting and follow-up | 27% fewer falls over 3 years | Audiology |
| Cataract surgery | Low thousands per eye | 34% fewer falls; dementia HR 0.71 (cohort) | Ophthalmology |
| Deprescribing review | A pharmacist's hour | Fewer falls and admissions | Pharmacy; primary care |
| Home hazard reduction (targeted) | Low hundreds to low thousands | 38% fewer falls at elevated risk | Occupational therapy |
| Social prescribing | Link-worker time; activity costs | Wellbeing and function; maturing | Primary care; community |
| Longevity clinic programme | Thousands per person per year | None | — |
| Biological-age testing programme | Hundreds per test | None | — |
| Companion-robot scheme | Hundreds to thousands per unit | Engagement only; outcomes null | — |
Frequently asked questions
What are the most cost-effective public longevity infrastructure solutions for healthy ageing?
Ranked on cost per healthy life-year in older adults: adult vaccination through pharmacies; hypertension control with pharmacist- or nurse-led titration; physiotherapist-led falls-prevention exercise; hearing-aid provision with follow-up; timely cataract surgery; structured deprescribing services; targeted home hazard reduction; and social prescribing. Publicly funded longevity clinics, biological-age testing and robot or device schemes are cost-ineffective at any price.
Is falls-prevention exercise cost-effective?
Yes. Balance and functional exercise cuts falls by 23% across 108 randomised trials with high certainty, more with resistance training added, and is cost-effective against the costs of hip fracture and care-home admission it prevents. It is delivered to a small fraction of eligible older adults, which is why fall deaths have risen despite the evidence.
Are hearing aids a cost-effective healthy-ageing intervention?
Where they are fitted properly and actually worn: hearing intervention cut falls by 27% over three years, and in the ACHIEVE trial slowed cognitive decline by 61.6% in the highest-risk quartile (the overall primary result was null). The cost that is wasted is the device that sits in a drawer, so fitting, follow-up and adherence support are part of the intervention.
Why is deprescribing on a cost-effectiveness list?
Because sedatives, anticholinergics, opioids and over-treated blood pressure cause falls, delirium and admissions in older adults, and a pharmacist-led review with authority to stop them reduces that harm in trials at the cost of an hour's time. It is among the cheapest healthy-ageing interventions available and is funded patchily because it lives in the medicines budget rather than the strategy.
Is home hazard reduction worth funding for everyone?
No — and that is the evidence. Occupational-therapist-led home modification cuts falls by 38% in people already at elevated risk, with high certainty, and has no effect in unselected populations, also with high certainty. It is cost-effective only when targeted at the people who need it, which makes targeting the intervention.
Why are longevity clinics and biological-age tests not cost-effective for public health?
Because they buy no healthy years: no evidence shows a longevity-clinic programme or an epigenetic-age testing scheme adds healthy life at population scale, and companion-robot and fall-detection schemes have null or absent outcome trials. They cost more per person than the entire list of proven interventions and displace budget from it.
Keep reading
- Which public longevity infrastructure solutions offer best ROI?
The same question with the ROI caveats.
- Longevity technology
The falls, hearing and cataract evidence in detail.
- Public health and policy
The prevention economics.
- Free stack check
Deprescribing, delivered.
More in Public health & policy
- What is public longevity infrastructure and why it matters?
Public longevity infrastructure defined — the laws, budgets, services and built environment a government uses to extend healthy life — and its components ranked by evidence: tobacco and alcohol policy, vaccination and screening delivery, hypertension control, primary and pharmacy care, air quality and active-travel design, falls prevention, and longevity research — with why the morbidity gap makes it matter now.
- How to invest in public longevity infrastructure projects?
How private capital can invest in public longevity infrastructure, ranked by instrument and project type: municipal and sovereign health bonds, social and health impact bonds, public-private partnerships for primary-care and diagnostic facilities, listed healthcare-infrastructure and REIT exposure, and impact funds — with what returns are realistic, what 'longevity dividend' figures actually mean, and the questions to ask before committing.
- Which public longevity infrastructure solutions offer best ROI?
Public longevity infrastructure solutions ranked on return per healthy life-year with the evidence caveats stated: tobacco and alcohol taxation, salt and sugar policy, vaccination delivery, hypertension control, cessation services, falls-prevention exercise, screening programmes, active-travel infrastructure, and longevity clinics or research institutes — with why ROI figures vary from negative to 30:1 and what a treasury should actually expect.
- How can governments fund public longevity infrastructure effectively?
Funding mechanisms for public longevity infrastructure ranked on whether money reaches delivery and survives budget cycles: earmarked health taxes, legally reserved prevention shares (EU4Health's 20%), ring-fenced prevention budgets, outcome-linked payments, general taxation with performance frameworks, and one-off capital programmes — with the evidence from the EU, UK and Singapore on what holds and what evaporates.
- What public longevity infrastructure strategies improve population health outcomes?
Public longevity strategies ranked on recorded population-health outcomes: fiscal and regulatory control of tobacco, alcohol and diet; universal primary care with enrolment (Singapore's Healthier SG model); organised vaccination and screening with call-recall; hypertension control at scale; deprivation-targeted delivery to close the 20-year healthy-life gap; healthy-ageing services; and target-led strategies without delivery — with what each has actually changed.
- How to evaluate impact of public longevity infrastructure?
A ranked method for evaluating public longevity infrastructure: pick outcomes that matter (healthy life expectancy by deprivation, morbidity gap), use designs that can attribute (randomised rollouts, stepped-wedge, difference-in-differences, synthetic controls), track delivery and coverage first, measure equity, model cost-effectiveness honestly, and avoid the evaluation traps that let target-led strategies claim success.